Progentec Diagnostics, Inc.

Progentec Diagnostics, Inc. is a biotechnology company that develops innovative diagnostic solutions for autoimmune diseases, focusing on lupus and multiple sclerosis management through advanced molecular testing. Progentec Diagnostics, Inc. specializes in diagnostic solutions for autoimmune diseases.

Founded in 2015, the company is headquartered in Oklahoma City, US. It has undergone three significant funding deals, with the latest being a Series A round in January 2020, raising USD 5. 000 mn. The founder, Brett Adelman, has a history of entrepreneurship, although specific prior ventures are not detailed.

Progentec Diagnostics, Inc. specializes in innovative diagnostic solutions aimed at managing autoimmune diseases, particularly lupus and multiple sclerosis (MS). The company's flagship product, the aiSLE™ DX Flare Risk Index, utilizes proprietary LiquidFlareRisk™ Technology to assess the risk of lupus patients experiencing disease-related flares within a 12-week timeframe. Released in April 2020, this molecular diagnostic test provides critical insights that traditional disease activity scales do not offer.

Additionally, Progentec is developing biological and digital biomarkers that enhance the monitoring of MS disease progression, employing blood tests and cognitive assessments. These products cater to healthcare professionals, researchers, and over 120,000 lupus patients and caregivers through the LupusCorner platform. Progentec Diagnostics operates within a transactional framework encompassing direct-to-consumer and business-to-business engagements. The company generates revenue through the sale of diagnostic tests, including the aiSLE™ DX Flare Risk Index, to medical facilities and laboratories, such as Mayo Clinic Laboratories.

The pricing strategy reflects individual test purchases as well as bulk orders for healthcare providers, ensuring accessibility across various geographical markets in the management of autoimmune diseases. Progentec Diagnostics is focused on expanding its product line and market presence. The company plans to launch new products designed to enhance autoimmune disease management by mid-2023. Recent Series A funding of USD 5.

000 mn will be utilized to support the development and market introduction of these upcoming products, as well as to facilitate expansion into new geographic regions, specifically targeting European and Asian markets by 2024. This strategic approach aims to leverage their existing platforms and collaborations to improve healthcare outcomes for patients with autoimmune conditions.